Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
Aim. To assess the efficacy profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib — novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA). Materials and methods. Randomized controlled trials of tofacitinib, baricitinib and upadacitinib i...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Izdatelstvo OKI
2024-02-01
|
| Series: | Качественная клиническая практика |
| Subjects: | |
| Online Access: | https://www.clinvest.ru/jour/article/view/693 |
| _version_ | 1797262021598642176 |
|---|---|
| author | A. E. Cheberda D. Yu. Belousov |
| author_facet | A. E. Cheberda D. Yu. Belousov |
| author_sort | A. E. Cheberda |
| collection | DOAJ |
| description | Aim. To assess the efficacy profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib — novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA). Materials and methods. Randomized controlled trials of tofacitinib, baricitinib and upadacitinib in RA were identified from MEDLINE, and Cochrane databases. Random- effects models were used to estimate pooled mean differences (MD) and relative risks (RRs). American College of Rheumatology 20 % (ACR20), Health Assessment Questionnaire–Disability Index (HAQ-DI) were calculated. Results. Twenty trials with an overall low risk of bias were identified. Tofacitinib, baricitinib, and upadacitinib improved RA control as deter -mined by ACR20 (RR, 2.03; 95 % CI, 1.87 to 2.20) and HAQ-DI (MD, −0.31; 95% CI, −0.34 to −0.28) compared with placebo. Conclusion. Tofacitinib, baricitinib, and upadacitinib significantly improve RA control. To make further decisions, comparative clinical trials of the Janus kinase inhibitors in the real-world clinical practice are necessary. |
| first_indexed | 2024-04-24T23:50:29Z |
| format | Article |
| id | doaj.art-17035698925941c8bfee596dca472743 |
| institution | Directory Open Access Journal |
| issn | 2588-0519 2618-8473 |
| language | Russian |
| last_indexed | 2024-04-24T23:50:29Z |
| publishDate | 2024-02-01 |
| publisher | Izdatelstvo OKI |
| record_format | Article |
| series | Качественная клиническая практика |
| spelling | doaj.art-17035698925941c8bfee596dca4727432024-03-14T18:09:10ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732024-02-01049610710.37489/2588-0519-2023-4-96-10650Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysisA. E. Cheberda0D. Yu. Belousov1ООО «Центр фармакоэкономических исследованияООО «Центр фармакоэкономических исследованияAim. To assess the efficacy profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib — novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA). Materials and methods. Randomized controlled trials of tofacitinib, baricitinib and upadacitinib in RA were identified from MEDLINE, and Cochrane databases. Random- effects models were used to estimate pooled mean differences (MD) and relative risks (RRs). American College of Rheumatology 20 % (ACR20), Health Assessment Questionnaire–Disability Index (HAQ-DI) were calculated. Results. Twenty trials with an overall low risk of bias were identified. Tofacitinib, baricitinib, and upadacitinib improved RA control as deter -mined by ACR20 (RR, 2.03; 95 % CI, 1.87 to 2.20) and HAQ-DI (MD, −0.31; 95% CI, −0.34 to −0.28) compared with placebo. Conclusion. Tofacitinib, baricitinib, and upadacitinib significantly improve RA control. To make further decisions, comparative clinical trials of the Janus kinase inhibitors in the real-world clinical practice are necessary.https://www.clinvest.ru/jour/article/view/693ревматоидный артриттофацитиниббарицитинибупадацитинибингибиторы янус-киназсистематический обзорметаанализhaq-diacr20 |
| spellingShingle | A. E. Cheberda D. Yu. Belousov Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis Качественная клиническая практика ревматоидный артрит тофацитиниб барицитиниб упадацитиниб ингибиторы янус-киназ систематический обзор метаанализ haq-di acr20 |
| title | Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis |
| title_full | Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis |
| title_fullStr | Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis |
| title_full_unstemmed | Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis |
| title_short | Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis |
| title_sort | effectiveness of janus kinase inhibitors in rheumatoid arthritis systematic review and meta analysis |
| topic | ревматоидный артрит тофацитиниб барицитиниб упадацитиниб ингибиторы янус-киназ систематический обзор метаанализ haq-di acr20 |
| url | https://www.clinvest.ru/jour/article/view/693 |
| work_keys_str_mv | AT aecheberda effectivenessofjanuskinaseinhibitorsinrheumatoidarthritissystematicreviewandmetaanalysis AT dyubelousov effectivenessofjanuskinaseinhibitorsinrheumatoidarthritissystematicreviewandmetaanalysis |